Intensive Care Unit, Centre Hospitalier de Versailles-Site André Mignot, 177, rue de Versailles, 78150 Le Chesnay cedex, France.
Microbiology Laboratory, Centre Hospitalier de Versailles, Le Chesnay, France.
Infect Dis Now. 2021 Jun;51(4):383-386. doi: 10.1016/j.idnow.2020.12.008. Epub 2021 Jan 18.
Invasive pulmonary aspergillosis is a well-known complication of acute respiratory distress syndrome, the most serious manifestation of COVID-19. Four recent studies have reported its incidence among ICU COVID-19 patients. However, they do not share the same case definition, and have provided conflicting results. In this paper we have aimed at reported the incidence of invasive pulmonary aspergillosis for COVID-19 patients in our ICU, and at comparing the different definitions in order to assess their respective relevance.
Retrospective cohort study of critically ill patients with severe COVID-19 requiring ICU management between 1st March and 30th April 2020.
Our results showed significantly lower incidence of invasive pulmonary aspergillosis (1.8%;1/53), compared to three out of four previous studies, and wide variation in the numbers of cases with regard to the different definitions.
Large-scale studies are needed for a better definition and a more accurate estimation of invasive pulmonary aspergillosis coinfection during COVID-19.
侵袭性肺曲霉病是急性呼吸窘迫综合征(COVID-19 最严重的表现)的一种已知并发症。四项最近的研究报告了 ICU COVID-19 患者中该病的发病率。然而,它们没有使用相同的病例定义,且提供了相互矛盾的结果。在本文中,我们旨在报告我们 ICU 中 COVID-19 患者侵袭性肺曲霉病的发病率,并比较不同的定义,以评估它们各自的相关性。
这是一项回顾性队列研究,纳入了 2020 年 3 月 1 日至 4 月 30 日期间需要 ICU 管理的重症 COVID-19 危重病患者。
与四项研究中的三项相比,我们的结果显示侵袭性肺曲霉病的发病率明显较低(1.8%;53 例中有 1 例),且不同定义的病例数量差异很大。
需要开展大规模研究以更好地定义和更准确地估计 COVID-19 期间侵袭性肺曲霉病合并感染。